The ATS Research Program Benefit is an annual fundraising event at the ATS International Conference and an opportunity to contribute to and celebrate the Research Program’s support of early career investigators who are dedicated to respiratory breakthroughs and improving the lives of patients.

This year’s Benefit will be held from 6 – 7:30 p.m. on Saturday, May 17, at the San Francisco Marriott Marquis. Tickets include a tax-deductible donation to the ATS Research Program and may be purchased on their own or as part of ATS 2025 registration. Hors-d’oeuvres, beer, and wine will be served at the event, and business attire is recommended.

In its first 20 years, the ATS Research Program has invested approximately $25 million to support 427 research grants led by early career investigators in the United States and abroad. 

“The ATS prioritizes supporting respiratory research and future generations of leaders in pulmonary, critical care, and sleep medicine. The ATS Research Program Benefit is a much-anticipated opportunity each year to reconnect with other International Conference attendees and support a critical organizational initiative,” said ATS President Irina Petrache, MD, ATSF.

General admission tickets are $350 ($200 tax-deductible), while “Founder” ticket packages are $1,000 ($700 tax-deductible) and include two tickets to the benefit, an invitation to the VIP Donor Reception at ATS 2025, and access to the Donor Café.

Corporate and Institutional sponsorship packages, which include logo recognition and other benefits, can be purchased through ATS 2025 International Conference registration or by contacting ATS Philanthropy Director Delia Naughton, LMSW, at [email protected].

The ATS also invites its industry friends to sponsor and attend this important event. For questions, please email Meredith Smalstig, Associate Director, Sponsorships and Industry Programs, at [email protected].

More information about ticket packages and sponsorship opportunities can be found at https://conference.thoracic.org/program/events/research-program-benefit.php. For additional questions about the ATS Research Program Benefit, please email [email protected].

The ATS thanks Chiesi USA, GSK, Boehringer Ingelheim Pharmaceuticals, Inc., Genentech, Inc., GSK, Insmed Incorporated, and Sanofi | Regeneron for their support of the ATS 2025 Research Program Benefit.